A Proof-of-Concept Study of VK2809 for the Treatment of Glycogen Storage Disease Type Ia (GSD Ia)
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs VK 2809 (Primary)
- Indications Glycogen storage disease type I
- Focus Adverse reactions; Proof of concept
- Sponsors Viking Therapeutics
- 28 Aug 2018 I have assumed 1 Sep 2018 as planned start date (third quarter-July passed and Aug almost passed).Also, I have assumed trial focus as AR based on trial phase (I).Please update it according to registry source primary endpoints.
- 09 Aug 2018 According to a Viking Therapeutics media release, the company plans to begin dosing patients in this trial in the third quarter of 2018.
- 17 Feb 2017 New trial record